Norwegian pharmaceutical developer Nycomed continues to be plagued by lower x-ray contrast media prices. The Oslo company this month released first-quarter financial results that showed lower revenues and net income for the period.For the quarter,
Norwegian pharmaceutical developer Nycomed continues to be plagued by lower x-ray contrast media prices. The Oslo company this month released first-quarter financial results that showed lower revenues and net income for the period.
For the quarter, Nycomed had operating revenues of $257.4 million (1.84 billion Norwegian krone), a drop of 7% compared with revenues of $277.4 million in the first quarter of 1996. Nycomed's net income was $25 million, compared with $37 million in the same period last year.
Nycomed said the major factor behind the revenue shortfall was the fact that x-ray contrast media prices in the U.S. were 30% lower in the first quarter of 1997 compared with the first quarter of 1996. Prices, which began dropping early last year, stabilized toward the end of 1996, and remained relatively unchanged in the first quarter of 1997. Additional pressure could be looming, however, as two group purchasing organizations in the U.S. are expected to renegotiate their supply agreements for contrast in the second half of this year.
Nycomed also reported that sales of its Omniscan MRI contrast agent declined in both volume and value in the U.S. compared with the first quarter of 1996, while price pressure also hit the MRI contrast market. Omniscan sales outside the U.S. grew 30%, however.
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.